lifePR
Pressemitteilung BoxID: 529566 (4SC AG)
  • 4SC AG
  • Fraunhoferstr. 22
  • 82152 Planegg-Martinsried
  • http://www.4sc.de
  • Ansprechpartner
  • Jochen Orlowski
  • +49 (89) 700763-66

4SC AG plans Extraordinary General Meeting and reduction of share capital

(lifePR) (Planegg-Martinsried, Germany, ) 4SC AG (Frankfurt, Prime Standard: VSC) today decided to hold an Extraordinary General Meeting on 11 March 2015. The primary objective of the Extraordinary General Meeting is to adopt a resolution to reduce the Company's share capital through a reverse split of shares in accordance with sections 222 ff. of the German Stock Corporation Act (AktG). The capital reduction is to be effected such that the share capital is lowered from EUR 50,849,205.00 by EUR 40,679,364.00 to EUR 10,169,841.00 by consolidating the no-par value shares issued in a 5:1 ratio from 50,849,205 to 10,169,841.

From an accounting perspective, the capital reduction is intended to effect a reclassification on the liabilities side of the balance sheet of 4SC AG from subscribed capital to the non-distributable capital reserves. This measure will not change the Company's equity structure and enterprise value. No distribution will be made to shareholders. The aim of the capital reduction is to raise the Company's share price in a sustained manner above the notional value of EUR 1.00 per share and to give 4SC AG the flexibility to undertake any future capital measures.

The resolution on the capital reduction will be preceded by a resolution to cancel one share of the Company surrendered to the Company by a shareholder free of charge (section 237(1) sentence 1, 2nd case in conjunction with section 237(3) No 1 AktG). This is necessary to be able to implement the capital reduction through consolidation of shares in an even share consolidation ratio.

Further information will be provided in the notice to the Extraordinary General Meeting which is expected to be published in the Federal Gazette on 29 January 2015.

Cautionary statement regarding forward-looking statements

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and 4SC AG has no obligation to update any such information or to correct any inaccuracies herein or omission herefrom which may become apparent.

4SC AG

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various cancer and autoimmune indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical and biotech companies. Founded in 1997, 4SC had a headcount of 66 employees (57 FTEs) at 31 December 2014. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.